Therapeutic heparin shows benefit in moderately-ill patients with Covid-19

Early initiation of therapeutic heparin should be considered in moderately ill hospitalised patients admitted for COVID-19, according to Canadian researchers whose trial showed it reduced the risk of death by almost 80%. While previous studies have not shown a benefit for therapeutic anticoagulation with DOACs in COVID-19, the researchers said heparin had additional anti-inflammatory and ...

Already a member?

Login to keep reading.

© 2021 the limbic